SFT2D2 and Familial prostate cancer: NEPC, an aggressive subtype evolved from CRPC, is typically resistant to nearly all current therapies.[42, 43] We found that SFT2D2‐TBX19 was gradually increased from castration‐resistant prostate cancer cell lines PC3, C4‐2, DU145, 22RV1 to neuroendocrine prostate cancer cell lines NCI‐H660.